BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parigi TL, D'Amico F, Peyrin-Biroulet L, Danese S. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opin Biol Ther 2021;21:37-46. [PMID: 32799561 DOI: 10.1080/14712598.2020.1811849] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Roblin X, Veyrard P, Bastide L, Berger AE, Barrau M, Paucelle AS, Waeckel L, Kwiatek S, Flourie B, Nancey S, Paul S. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease. Aliment Pharmacol Ther 2022;56:77-83. [PMID: 35229331 DOI: 10.1111/apt.16852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
2 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022;39:2342-64. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Caron B, Fumery M, Netter P, Peyrin-Biroulet L. Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure. Aliment Pharmacol Ther 2022;55:508-9. [PMID: 35092046 DOI: 10.1111/apt.16770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Manthey CF, Reher D, Huber S. [What is confirmed in the treatment of chronic inflammatory bowel diseases]. Internist (Berl) 2021. [PMID: 34727190 DOI: 10.1007/s00108-021-01207-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]